XML 162 R121.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Sales $ 64,168 $ 60,115 $ 59,283
Cost of sales 15,193 16,126 17,411
Selling, general and administrative 10,816 10,504 10,042
Research and development 17,938 30,531 13,548
Other segment items (24) 466 1,501
Income Before Taxes 19,936 1,889 16,444
Interest income 415 365 157
Interest expense (1,271) (1,146) (962)
Amortization (2,395) (2,044) (2,085)
Depreciation (2,104) (1,828) (1,824)
Research and development (17,938) (30,531) (13,548)
Restructuring costs (309) (599) (337)
Total segment profits      
Segment Reporting Information [Line Items]      
Sales 63,277 59,208 57,555
Income Before Taxes 46,471 40,617 38,815
Depreciation (261) (203) (182)
Total segment profits | Pharmaceutical      
Segment Reporting Information [Line Items]      
Sales 57,400 53,583 52,005
Cost of sales 6,828 8,849 9,678
Selling, general and administrative 6,128 5,903 5,474
Research and development 0 0 0
Other segment items (89) (49) 1
Income Before Taxes 44,533 38,880 36,852
Depreciation (5) (5) (5)
Research and development 0 0 0
Total segment profits | Animal Health      
Segment Reporting Information [Line Items]      
Sales 5,877 5,625 5,550
Cost of sales 2,469 2,498 2,259
Selling, general and administrative 1,084 1,038 999
Research and development 385 353 329
Other segment items 1 (1) 0
Income Before Taxes 1,938 1,737 1,963
Depreciation (256) (198) (177)
Research and development (385) (353) (329)
Other profits      
Segment Reporting Information [Line Items]      
Sales 891 907 1,728
Research and development 17,350 30,008 13,011
Income Before Taxes 492 474 1,160
Interest income 415 365 157
Interest expense (1,271) (1,146) (962)
Amortization (2,395) (2,044) (2,085)
Depreciation (1,843) (1,625) (1,642)
Research and development (17,350) (30,008) (13,011)
Restructuring costs (309) (599) (337)
Charge for Zetia antitrust litigation settlements 0 (573) 0
Other unallocated, net $ (4,274) $ (3,572) $ (5,651)